Healthcare · Medical - Devices
Price
$9.61
Market Cap
$651.1M
Employees
930
Beta
0.67
Avg Volume
572,264
CEO
Robert Claypoole
Business Description
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
23.11
Stock Price: $9.61
EPS (Diluted): 0.34
EPS (Diluted): 0.34
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.69
Stock Price: $9.61
Total Equity: $184.11M
Shares: 68,914,895
Total Equity: $184.11M
Shares: 68,914,895
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
8.70
Market Cap: $651.06M
Total Debt: $298.16M
Cash: $51.24M
EBITDA: $99.21M
Total Debt: $298.16M
Cash: $51.24M
EBITDA: $99.21M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$755.8M
Market Cap: $651.06M
Total Debt: $298.16M
Cash: $51.24M
Total Debt: $298.16M
Cash: $51.24M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
67.3%
Gross Profit: $382.43M
Revenue: $568.09M
Revenue: $568.09M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
10.3%
Operating Income: $58.55M
Revenue: $568.09M
Revenue: $568.09M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
4.0%
Net Income: $22.73M
Revenue: $568.09M
Revenue: $568.09M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
16.3%
Net Income: $22.73M
Total Equity: $184.11M
Total Equity: $184.11M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
11.8%
Operating Income: $58.55M
Tax Rate: -6.1%
Equity: $184.11M
Total Debt: $298.16M
Cash: $51.24M
Tax Rate: -6.1%
Equity: $184.11M
Total Debt: $298.16M
Cash: $51.24M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.70
Current Assets: $272.84M
Current Liabilities: $160.38M
Current Liabilities: $160.38M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
1.62
Short-Term Debt: $19.21M
Long-Term Debt: $278.95M
Total Debt: $298.16M
Total Equity: $184.11M
Long-Term Debt: $278.95M
Total Debt: $298.16M
Total Equity: $184.11M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$8.24
Revenue: $568.09M
Shares: 68,914,895
Shares: 68,914,895
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.67
Total Equity: $184.11M
Shares: 68,914,895
Shares: 68,914,895
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$1.04
Operating CF: $73.98M
CapEx: -$2.56M
Shares: 68,914,895
CapEx: -$2.56M
Shares: 68,914,895
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $9.61
Stock Price: $9.61
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $22.73M
Net Income: $22.73M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BVS against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 1:21am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Cost of Revenue | $128.2M | $181.0M | $184.2M | $185.1M | $185.7M |
| Gross Profit | $302.7M | $331.1M | $328.2M | $388.2M | $382.4M |
| Operating Expenses | $290.6M | $498.3M | $409.9M | $400.2M | $323.9M |
| Operating Income | $12.1M | -$167.2M | -$81.7M | -$12.0M | $58.5M |
| Net Income | $19.4M | -$158.7M | -$156.2M | -$33.5M | $22.7M |
| EBITDA | $45.5M | -$121.6M | -$23.1M | $39.2M | $99.2M |
| EPS | $-0.15 | $-2.59 | $-2.49 | $-0.52 | $0.34 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 1:21am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $43.9M | $30.2M | $37.0M | $41.6M | $51.2M |
| Total Current Assets | $263.1M | $272.6M | $268.0M | $275.6M | $272.8M |
| Total Assets | $1.2B | $1.4B | $810.9M | $728.0M | $683.6M |
| Current Liabilities | $180.9M | $304.0M | $175.5M | $210.4M | $160.4M |
| Long-Term Debt | $339.6M | $385.0M | $367.0M | $308.3M | $279.0M |
| Total Liabilities | $692.1M | $960.4M | $589.8M | $542.4M | $455.1M |
| Total Equity | $458.9M | $325.2M | $173.6M | $147.9M | $184.1M |
| Retained Earnings | -$6.6M | -$165.3M | -$321.5M | -$355.1M | -$334.9M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 1:21am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $23.0M | -$13.5M | $15.3M | $38.8M | $74.0M |
| Capital Expenditure | -$20.9M | -$1.5M | -$7.4M | -$1.0M | -$2.6M |
| Free Cash Flow | $2.1M | -$15.0M | $8.0M | $37.8M | $71.4M |
| Acquisitions (net) | -$262.9M | $0 | $34.7M | $0 | $-686,000 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $12.4M | -$67.4M | $5.1M | $4.6M | $9.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 2:26pm (18h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$645.5M $636.8M – $654.1M
|
$685.3M $685.3M – $685.3M
|
$737.1M $731.4M – $744.2M
|
$793.4M $787.2M – $801.0M
|
| EBITDA |
$8.5M $8.4M – $8.6M
|
$9.1M $9.1M – $9.1M
|
$9.7M $9.7M – $9.8M
|
$10.5M $10.4M – $10.6M
|
| Net Income |
$62.1M $61.1M – $63.2M
|
$74.7M $52.7M – $96.7M
|
$73.7M $73.0M – $74.7M
|
$84.8M $83.9M – $85.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 1:21am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +18.8% | +0.0% | +11.9% | -0.9% |
| Gross Profit Growth | +9.4% | -0.9% | +18.3% | -1.5% |
| Operating Income Growth | -1,486.6% | +51.1% | +85.3% | +588.7% |
| Net Income Growth | -919.1% | +1.6% | +78.5% | +167.8% |
| EBITDA Growth | -367.4% | +81.0% | +270.0% | +152.9% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:24am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-02 | Bartholdson John A. | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | Bartholdson John A. | A-Award | 25,146.00 | $0.00 | $0 |
| 2026-06-02 | Bartholdson John A. | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-02 | SUTTER MARTIN P | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | SUTTER MARTIN P | A-Award | 25,146.00 | $0.00 | $0 |
| 2026-06-02 | SUTTER MARTIN P | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-02 | STALNECKER SUSAN M | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | STALNECKER SUSAN M | A-Award | 25,146.00 | $0.00 | $0 |
| 2026-06-02 | STALNECKER SUSAN M | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-02 | NOHRA GUY P | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | NOHRA GUY P | A-Award | 25,146.00 | $0.00 | $0 |
| 2026-06-02 | NOHRA GUY P | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-02 | NEELS GUIDO J | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | NEELS GUIDO J | A-Award | 25,146.00 | $0.00 | $0 |
| 2026-06-02 | NEELS GUIDO J | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-02 | McMurry-Heath Michelle | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | McMurry-Heath Michelle | A-Award | 25,146.00 | $0.00 | $0 |
| 2026-06-02 | McMurry-Heath Michelle | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-02 | Ladone Mary Kay | M-Exempt | 32,282.00 | $0.00 | $0 |
| 2026-06-03 | Ladone Mary Kay | A-Award | 25,146.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BVS — it's generated by the pipeline (
market-narrative step).
No community reviews yet for BVS.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30